The Venous Leg Ulcers (Crural Ulcer) drugs in development market research report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural Ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Venous Leg Ulcers (Crural Ulcer). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Venous Leg Ulcers (Crural Ulcer) and features dormant and discontinued products.

GlobalData tracks 17 drugs in development for Venous Leg Ulcers (Crural Ulcer) by 16 companies/universities/institutes. The top development phase for Venous Leg Ulcers (Crural Ulcer) is phase ii with ten drugs in that stage. The Venous Leg Ulcers (Crural Ulcer) pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Venous Leg Ulcers (Crural Ulcer) pipeline products market are: MediWound, GangaGen Biotechnologies and Promore Pharma.

The key targets in the Venous Leg Ulcers (Crural Ulcer) pipeline products market include C Type Lectin Domain Family 7 Member A (Beta Glucan Receptor or C Type Lectin Superfamily Member 12 or Dendritic Cell Associated C Type Lectin 1 or Dectin 1 or CLEC7A), Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31), and Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1).

The key mechanisms of action in the Venous Leg Ulcers (Crural Ulcer) pipeline product include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) Activator with one drug in Phase II. The Venous Leg Ulcers (Crural Ulcer) pipeline products include eight routes of administration with the top ROA being Topical and six key molecule types in the Venous Leg Ulcers (Crural Ulcer) pipeline products market including Cell Therapy, and Small Molecule.

Venous Leg Ulcers (Crural Ulcer) overview

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles with pitting edema (fluid-filled tissue that temporarily holds the imprint of a finger when pressed); hemosiderosis (discoloration and darkening of the skin around the ulcer); lipodermatosclerosis, hardened skin around the ulcer that may make the leg feel hard and resemble the shape of an upside-down champagne bottle; and atrophie blanche, small, smooth areas of white skin that may have tiny red spots.

For a complete picture of Venous Leg Ulcers (Crural Ulcer)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.